Rockwell Medical (RMTI) Non-Current Deffered Revenue (2016 - 2024)
Rockwell Medical (RMTI) posted Non-Current Deffered Revenue of $429000.0 for Q4 2024, down 2.72% on a QoQ basis from $441000.0 in Q3 2024, and down 9.68% year-over-year from $475000.0 in Q1 2024.
Rockwell Medical (RMTI) Non-Current Deffered Revenue (2016 - 2024) Analysis & Trends
Rockwell Medical's Non-Current Deffered Revenue history runs 9 years deep, the most recent figure standing at $429000.0 for Q4 2024.
- Quarterly Non-Current Deffered Revenue fell 9.68% year-over-year to $429000.0 in Q4 2024, while the trailing twelve-month figure through Dec 2024 was $429000.0 (down 9.68% YoY) and the FY2024 annual result came in at $429000.0, down 9.68% from the prior year.
- Non-Current Deffered Revenue was $429000.0 for Q4 2024 at Rockwell Medical, down from $441000.0 in the prior quarter.
- Across five years, Non-Current Deffered Revenue topped out at $9.5 million in Q1 2020 and bottomed at $429000.0 in Q4 2024.
- A 5-year average of $4.4 million and a median of $4.8 million in 2022 frame the typical range for Non-Current Deffered Revenue.
- Annual changes were most pronounced in 2023 — Non-Current Deffered Revenue tumbled 89.33% — and 2024, when it slipped 9.45%.
- Rockwell Medical's Non-Current Deffered Revenue stood at $8.0 million in 2020, then slipped by 25.32% to $6.0 million in 2021, then tumbled by 56.57% to $2.6 million in 2022, then slumped by 81.73% to $475000.0 in 2023, then decreased by 9.68% to $429000.0 in 2024.
- Business Quant data shows RMTI's Non-Current Deffered Revenue at $429000.0 in Q4 2024, $441000.0 in Q3 2024, and $452000.0 in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | - |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | - |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | - |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | - |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | - |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | - |
| 10 | Rockwell Medical | 25.77 Mn | 1.88 Mn | 2.90 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 429,000.00 |
| Sep 30, 2024 | 441,000.00 |
| Jun 30, 2024 | 452,000.00 |
| Mar 31, 2024 | 464,000.00 |
| Dec 31, 2023 | 475,000.00 |
| Sep 30, 2023 | 487,000.00 |
| Jun 30, 2023 | 2.47 Mn |
| Mar 31, 2023 | 2.54 Mn |
| Dec 31, 2022 | 2.60 Mn |
| Sep 30, 2022 | 4.57 Mn |
| Jun 30, 2022 | 5.11 Mn |
| Mar 31, 2022 | 5.46 Mn |
| Dec 31, 2021 | 5.99 Mn |
| Sep 30, 2021 | 6.53 Mn |
| Jun 30, 2021 | 6.94 Mn |
| Mar 31, 2021 | 7.48 Mn |
| Dec 31, 2020 | 8.02 Mn |
| Sep 30, 2020 | 8.56 Mn |
| Jun 30, 2020 | 8.91 Mn |
| Mar 31, 2020 | 9.45 Mn |